iRadimed (NASDAQ:IRMD) Sees Unusually-High Trading Volume – Here’s What Happened

iRadimed Corporation (NASDAQ:IRMD) shares saw unusually-strong trading volume on Friday . 172,292 shares were traded during trading, an increase of 63% from the previous session’s volume of 105,746 shares.The stock last traded at $94.3770 and had previously closed at $95.21.

Wall Street Analysts Forecast Growth

IRMD has been the topic of a number of recent analyst reports. Freedom Capital upgraded iRadimed to a “strong-buy” rating in a research report on Thursday, April 2nd. Weiss Ratings cut shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $120.00.

iRadimed Trading Down 1.8%

The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of 51.11 and a beta of 0.90. The company has a fifty day moving average of $94.56 and a 200-day moving average of $95.73.

iRadimed (NASDAQ:IRMD) last announced its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.03. The business had revenue of $21.98 million during the quarter, compared to analysts’ expectations of $21.32 million. iRadimed had a return on equity of 24.48% and a net margin of 27.36%. As a group, equities research analysts expect that iRadimed Corporation will post 1.52 EPS for the current year.

Insider Activity at iRadimed

In related news, CEO Roger E. Susi sold 2,500 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $90.60, for a total value of $226,500.00. Following the completion of the transaction, the chief executive officer directly owned 2,162,500 shares of the company’s stock, valued at approximately $195,922,500. This represents a 0.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 21,250 shares of company stock worth $1,836,403 in the last three months. 34.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On iRadimed

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quarry LP purchased a new stake in shares of iRadimed during the third quarter worth $40,000. Farther Finance Advisors LLC lifted its stake in shares of iRadimed by 827.1% in the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $43,000 after buying an additional 397 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 495 shares in the last quarter. CWM LLC boosted its position in iRadimed by 19.5% during the fourth quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock worth $64,000 after acquiring an additional 107 shares during the last quarter. Finally, Global Retirement Partners LLC purchased a new stake in iRadimed during the 4th quarter valued at about $85,000. Institutional investors and hedge funds own 92.34% of the company’s stock.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.